- Home
- HEPS vs KURA Comparison
HEPS vs KURA Comparison
Compare HEPS & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | KURA |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.0M | 765.8M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | HEPS | KURA |
|---|---|---|
| Price | $2.68 | $9.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $3.07 | ★ $25.56 |
| AVG Volume (30 Days) | 266.4K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | $41.29 | $28.28 |
| Revenue Next Year | $27.99 | $106.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $2.15 | $5.45 |
| 52 Week High | $3.30 | $12.49 |
Technical Indicators
Market Signals| Indicator | HEPS | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 61.37 |
| Support Level | $2.66 | $8.81 |
| Resistance Level | $2.95 | $10.34 |
| Average True Range (ATR) | 0.07 | 0.39 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 7.50 | 80.14 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.